ScinoPharm’s Tainan, Taiwan Facility will provide commercial manufacture of topiramate API for VIVUS' Qsymia, a recently approved drug for the treatment of obesity. Qsymia is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related comorbidity. It is a combination of an anticonvulsant, topiramate, and appetite suppressant, phentermine.
"ScinoPharm is proud of our longstanding partnership with VIVUS, which began with the supply of topiramate for the Qsymia clinical development program. We are committed to providing VIVUS and our other customers with high quality APIs, ensuring fast time-to-market," said Dr. Jo Shen, president and chief executive officer of ScinoPharm.
Additionally, ScinoPharm is expanding its manufacturing and process development capabilities through its new facility in Changshu, China, which will initially be used for the production of pharmaceutical intermediates with CGMP-grade API production planned for the near future. This expansion allows the company to support contract manufacturing services for clinical, small-scale, and commercial-stage APIs and intermediates.